Allianz Asset Management
TRIV

Allianz Asset Management’s TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK TRIV Stock Holding History

Allianz Asset Management’s Portfolio TRIV Stock Details TRIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-76,425
Closed -$961K – 2442
2014
Q4 		$961K Sell
76,425
-775
-1% -$10.6K ﹤0.01% 1832
2014
Q3 		$1.12M Buy
+77,200
New +$1.12M ﹤0.01% 1630

Other funds holding TRIV

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Allianz Asset Management's TRIV Position: Q1 2015 in Review

Allianz Asset Management sold out of TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK (TRIV) in Q1 2015, closing a stake of 76,425 shares — an estimated $961K sold.

Allianz Asset Management first reported a position in TRIV in Q3 2014 and held it in 2 quarters. The position peaked at $1.12M in Q3 2014. 38 funds tracked by Wall St. Rank hold TRIV as of Q1 2015.

  • Allianz Asset Management reported no remaining TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK position as of Q1 2015 after selling out during the quarter.
  • Allianz Asset Management sold 76,425 TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK shares in Q1 2015, an estimated $961K.
  • Allianz Asset Management first reported a position in TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK in Q3 2014 and held it in 2 quarters.
  • Allianz Asset Management's TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK position peaked at $1.12M in Q3 2014.
  • 38 funds tracked by Wall St. Rank held TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK as of Q1 2015.

Based on Allianz Asset Management's 13F filing for Q1 2015, filed 15 May 2015.